These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 8196727)
1. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064 [TBL] [Abstract][Full Text] [Related]
3. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208 [TBL] [Abstract][Full Text] [Related]
4. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529 [TBL] [Abstract][Full Text] [Related]
5. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103 [TBL] [Abstract][Full Text] [Related]
6. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530 [TBL] [Abstract][Full Text] [Related]
7. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504 [TBL] [Abstract][Full Text] [Related]
8. A comparison of budesonide with prednisolone for active Crohn's disease. Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530 [TBL] [Abstract][Full Text] [Related]
9. Natalizumab for active Crohn's disease. Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S; N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039 [TBL] [Abstract][Full Text] [Related]
10. Sargramostim for active Crohn's disease. Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ; N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384 [TBL] [Abstract][Full Text] [Related]
11. A preliminary study of growth hormone therapy for Crohn's disease. Slonim AE; Bulone L; Damore MB; Goldberg T; Wingertzahn MA; McKinley MJ N Engl J Med; 2000 Jun; 342(22):1633-7. PubMed ID: 10833209 [TBL] [Abstract][Full Text] [Related]
12. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group. Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074 [TBL] [Abstract][Full Text] [Related]
13. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827 [TBL] [Abstract][Full Text] [Related]
14. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579 [TBL] [Abstract][Full Text] [Related]
15. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders]. Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Mahdi G; Israel DM; Hassall E Am J Gastroenterol; 1996 Jul; 91(7):1355-9. PubMed ID: 8677994 [TBL] [Abstract][Full Text] [Related]
17. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ; Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865 [TBL] [Abstract][Full Text] [Related]